MedTrace Logo

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction

NCT05312021 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-05-15

No results posted yet for this study

Summary

This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The primary objective is to evaluate whether IMR-687 reduces NT-proBNP compared to placebo in these patients.

Conditions

Interventions

DRUG

IMR-687

150 mg and 200 mg tablets

OTHER

IMR-687 Placebo

Matching placebo to IMR-687

Sponsors & Collaborators

  • Imara, Inc.

    collaborator INDUSTRY

  • Cardurion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Steve Luperchio · Cardurion Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2023-09-30
Completion
2023-11-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312021 on ClinicalTrials.gov